#1 Clinical Trials Search in Europe

Trimodulin (Human Igm, Iga, Igg Solution)

Trimodulin, a human immunoglobulin solution containing IgM, IgA, and IgG, is being investigated as a potential treatment for severe community-acquired pneumonia (sCAP) and COVID-19 pneumonia. This article explores the ongoing clinical trials evaluating the efficacy and safety of Trimodulin in adult hospitalized patients with these conditions. The trials aim to assess whether Trimodulin, when used as an adjunctive therapy to standard of care, can improve outcomes and reduce mortality rates in patients with severe respiratory infections.

Table of Contents

What is Trimodulin?

Trimodulin, also known as BT588, is a novel medication being developed to treat severe respiratory infections[1]. It is a solution containing human immunoglobulins (antibodies) of three types: IgM, IgA, and IgG[2]. These antibodies are naturally occurring proteins in the human body that help fight infections. Trimodulin is derived from human blood plasma and is considered a biological product.

Medical Conditions Treated

Trimodulin is being studied for the treatment of two main conditions:

  • Severe Community-Acquired Pneumonia (sCAP): This is a serious lung infection that develops outside of hospitals or healthcare facilities[1].
  • Moderate to Severe COVID-19: This includes cases of COVID-19 that require hospitalization and oxygen support[2].

Both of these conditions can lead to severe respiratory distress and may be life-threatening, especially in adults.

How Trimodulin Works

Trimodulin works by supplementing the body’s natural immune response. The immunoglobulins in Trimodulin can:

  • Help neutralize harmful pathogens (disease-causing organisms)
  • Enhance the body’s ability to fight infections
  • Potentially reduce inflammation associated with severe respiratory infections

By providing additional antibodies, Trimodulin aims to boost the immune system’s capacity to combat severe pneumonia and COVID-19[1][2].

Administration and Dosage

Trimodulin is administered as an intravenous infusion, which means it is given directly into a vein. In clinical trials, it is being tested with the following parameters:

  • Given once daily for 5 consecutive days
  • Maximum daily dose: 191.2 mg/kg (milligrams per kilogram of body weight)
  • Maximum total dose: 956 mg/kg over the 5-day treatment period

The medication is given in addition to standard care treatments for pneumonia or COVID-19[1][2].

Clinical Trials

Trimodulin is currently being evaluated in Phase III clinical trials. These are large-scale studies designed to assess the efficacy and safety of the medication. Two main trials are ongoing:

  1. A study for adults hospitalized with severe community-acquired pneumonia (sCAP)[1]
  2. A study for adults hospitalized with non-severe community-acquired pneumonia (CAP) or moderate to severe COVID-19[2]

These trials are randomized, placebo-controlled, and double-blind, which means that participants are randomly assigned to receive either Trimodulin or a placebo, and neither the patients nor the researchers know who is receiving which treatment during the study.

Potential Benefits

The clinical trials aim to determine if Trimodulin can provide benefits such as:

  • Reduced mortality (death rate) at 28 and 90 days after treatment
  • Faster recovery from severe respiratory symptoms
  • Decreased need for mechanical ventilation
  • Shorter hospital and intensive care unit stays
  • Improved overall outcomes for patients with severe pneumonia or COVID-19

However, it’s important to note that these potential benefits are still being studied and have not yet been conclusively proven[1][2].

Safety and Side Effects

As Trimodulin is still in clinical trials, its full safety profile is not yet established. The trials are carefully monitoring for any adverse events (side effects) that may occur. Some potential concerns being watched for include:

  • Allergic reactions to the infusion
  • Thromboembolic events (blood clots)
  • Changes in kidney or liver function
  • Interactions with other medications

The trials are designed to collect comprehensive safety data to ensure that any risks associated with Trimodulin are well understood before it potentially becomes available for wider use[1][2].

Eligibility for Treatment

Currently, Trimodulin is only available through clinical trials. Eligibility criteria for these trials typically include:

  • Adults aged 18 or older
  • Hospitalization due to severe pneumonia or moderate to severe COVID-19
  • Need for oxygen support
  • Specific laboratory test results indicating severe inflammation

There are also several exclusion criteria, such as certain pre-existing medical conditions or use of specific medications, that may prevent participation in the trials[1][2].

It’s important to remember that Trimodulin is still an investigational treatment and is not yet approved for general use outside of clinical trials. Patients interested in this treatment should discuss their options with their healthcare providers, who can provide more information about potential eligibility for ongoing clinical trials.

Aspect Details
Drug Name Trimodulin (human IgM, IgA, IgG solution)
Conditions Studied Severe community-acquired pneumonia (sCAP), COVID-19 pneumonia
Trial Phase Phase III
Administration Intravenous infusion, once daily for 5 consecutive days
Primary Endpoint 28-day all-cause mortality rate, Composite deterioration/mortality rate
Key Secondary Endpoints 90-day mortality, clinical deterioration rates, time to recovery, safety assessments
Eligibility Criteria Adult hospitalized patients with sCAP or COVID-19 pneumonia, specific oxygen requirements
Follow-up Duration Up to 90 days
Key Exclusions Severe renal impairment, pre-existing severe lung diseases, decompensated heart failure

FAQ

  • What is Trimodulin? Trimodulin is a human immunoglobulin solution containing IgM, IgA, and IgG. It is being studied as a potential treatment for severe community-acquired pneumonia (sCAP) and COVID-19 pneumonia.
  • Who is eligible for the Trimodulin clinical trials? Eligible participants are adult hospitalized patients (18 years or older) with either severe community-acquired pneumonia or moderate to severe COVID-19 pneumonia. They must meet specific criteria regarding oxygen requirements and have radiological evidence of pneumonia.
  • How is Trimodulin administered in the trials? Trimodulin is administered intravenously once daily for 5 consecutive days, in addition to standard of care treatment for pneumonia.
  • What are the main objectives of the Trimodulin clinical trials? The main objectives are to assess the efficacy and safety of Trimodulin compared to placebo in reducing mortality rates and improving outcomes in patients with severe pneumonia or COVID-19.
  • How long do the Trimodulin clinical trials last? The trials include a treatment phase of 5 days, followed by a follow-up period of up to 90 days. Key assessments are made at day 28 and day 91 after treatment initiation.

Ongoing Clinical Trials on Trimodulin (Human Igm, Iga, Igg Solution)

  • Study of Trimodulin for Adults Hospitalized with Severe Community-Acquired Pneumonia

    Recruiting

    3 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Hungary +3

  • A study testing trimodulin in hospitalized adult patients with community-acquired pneumonia including COVID-19 pneumonia

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Hungary Latvia +3

Glossary

  • Community-acquired pneumonia (CAP): A type of pneumonia that is acquired outside of healthcare settings, typically in the community. It is often caused by bacteria or viruses and can range from mild to severe.
  • COVID-19 pneumonia: A severe complication of COVID-19 infection where the lungs become inflamed and filled with fluid, making breathing difficult.
  • Standard of Care (SoC): The typical treatment or care given to patients with a specific condition, based on current medical knowledge and practices.
  • Immunoglobulin: Proteins produced by the immune system that act as antibodies to fight infections and diseases.
  • Intravenous infusion: A method of delivering medications directly into the bloodstream through a vein.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a new treatment against no treatment.
  • Efficacy: The ability of a treatment to produce the desired beneficial effect under ideal circumstances.
  • Adverse event (AE): Any unfavorable and unintended sign, symptom, or disease that occurs during a clinical trial, which may or may not be related to the treatment being studied.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.

References

  1. http://clinicaltrials.eu/trial/study-of-trimodulin-for-adults-hospitalized-with-severe-community-acquired-pneumonia/
  2. http://clinicaltrials.eu/trial/study-of-trimodulin-for-adults-hospitalized-with-community-acquired-pneumonia-or-covid-19/